Arch Therapeutics Stock Today
| ARTH Stock | USD 0.21 0.01 4.55% |
Performance0 of 100
| Odds Of DistressLess than 46
|
Arch Therapeutics is trading at 0.21 as of the 24th of January 2025. This is a 4.55 percent decrease since the beginning of the trading day. The stock's open price was 0.22. Arch Therapeutics has 46 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. The performance scores are derived for the period starting the 28th of July 2024 and ending today, the 24th of January 2025. Click here to learn more.
Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company was founded in 2006 and is based in Framingham, Massachusetts. Arch Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange. The company has 249.94 M outstanding shares. More on Arch Therapeutics
Moving against Arch OTC Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Arch OTC Stock Highlights
| Business Concentration | Health Care, Health Care Equipment & Supplies, Biotechnology, Healthcare (View all Sectors) |
Arch Therapeutics [ARTH] is traded as part of a regulated electronic over-the-counter service offered by the NASD. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.44 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Arch Therapeutics's market, we take the total number of its shares issued and multiply it by Arch Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Arch Therapeutics conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 249.94 M outstanding shares.
Arch Therapeutics currently holds about 55 K in cash with (4.46 M) of positive cash flow from operations.
Check Arch Therapeutics Probability Of Bankruptcy
Ownership AllocationArch Therapeutics holds a total of 249.94 Million outstanding shares. Arch Therapeutics shows 14.58 percent of its outstanding shares held by insiders and 0.0 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Arch Ownership Details
Arch Therapeutics Risk Profiles
| Mean Deviation | 10.16 | |||
| Semi Deviation | 11.19 | |||
| Standard Deviation | 14.85 | |||
| Variance | 220.56 |
Arch Stock Against Markets
Picking the right benchmark for Arch Therapeutics otc stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Arch Therapeutics otc stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Arch Therapeutics is critical whether you are bullish or bearish towards Arch Therapeutics at a given time. Please also check how Arch Therapeutics' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Arch Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Diagnostics Now
Portfolio DiagnosticsUse generated alerts and portfolio events aggregator to diagnose current holdings |
| All Next | Launch Module |
Arch Therapeutics Corporate Management
Elected by the shareholders, the Arch Therapeutics' board of directors comprises two types of representatives: Arch Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Arch. The board's role is to monitor Arch Therapeutics' management team and ensure that shareholders' interests are well served. Arch Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Arch Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Abrams | Chief Officer | Profile | |
| Daniel Yrigoyen | VP Sales | Profile | |
| Terrence MD | Chairman, CoFounder | Profile | |
| Daniel Wadsworth | Advisor Commercialization | Profile | |
| Steven Kates | VP Technology | Profile | |
| Rutledge EllisBehnke | CoFounder Advisor | Profile |
Other Information on Investing in Arch OTC Stock
Arch Therapeutics financial ratios help investors to determine whether Arch OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Arch with respect to the benefits of owning Arch Therapeutics security.